Orchid Pharma rises 4% on deal with Cipla to roll out new UTI drug in India
The rise came following Orchid Pharma's announcement of a collaboration with pharmaceutical giant Cipla to introduce the antibiotic Cefepime-Enmetazobactam in India Orchid Pharma ties up with Cipla for new UTI drug's distribution
It is estimated that the drug sales could reach an annual value of about 100 crore, in about 2-3 years Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release titled as "Orchid Pharma partners with Cipla to launch antibiotic Cefepime-Enmetazobactam in India" is being released by the Company. Orchid Pharma Ltd - 524372 - Closure of Trading Window
Intimation for closure of Trading Window for the Quarter/period ending on June 30, 2024 Orchid Pharma blossoms with new blockbuster drug
The pharma company's India-discovered drug Enmetazobactum, the first to receive US FDA approval, will help it flower with strength Orchid Pharma Ltd - 524372 - Investor Roadshows Scheduled To Be Held On June 18 And 19, 2024
The Company will be participating in Investor Road Show Scheduled to be held on June 18 and 19, 2024. Orchid to launch Enmetazobactum by next quarter
Seeks permission from Tamil Nadu government to manufacture the drug at its Chennai plant
Orchid Pharma Gets Green Light From DCGI For New Antibiotic Drug
Orchid Pharma receives approval from DCGI to manufacture new antibiotic drug for complicated urinary tract infections. Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release- Orchid Pharma receives DCGI approval for its first invented and made-in-antibiotic Drug combination of Cefepime and Enmetazobactam (NCE). Orchid Pharma Ltd - 524372 - Investor Roadshows Scheduled To Be Held On June 05 And 06, 2024
Company will participate in Investor Roadshow scheduled to be held on June 05 and June 06, 2024